The primary objective of the activities proposed in this application is to provide optical coherence tomography (OCT) Reading Center support to the Comparison of Age Related Macular Degeneration Treatment trials (CATT). The long term goals of this project, that will be accomplished through conduct of specific CATT studies are 1) to identify by OCT those eyes that are most likely to benefit from preventative strategies or treatments designed to prevent vision loss, or improve visual acuity in eyes with AMD, 2) to determine by OCT when treatment is effective or re-treatment is required and 3) to standardize OCT protocols and grading methods in eyes with AMD. The primary objective will be accomplished through the following specific aims:
Specific Aim 1 : Establish the infrastructure to process OCT images that will be submitted by CATT clinical centers to the CATT OCT Reading Center.
Specific Aim 2 : Collaborate with the Coordinating Center to establish and implement OCT certification and training programs for CATT clinical study investigators, clinical coordinators and OCT technicians in preparation for CATT.
Specific Aim 3 : Provide reliable, timely, reproducible, and systematic grading of submitted OCT materials. To achieve these aims, The OCT Reading Center will use a custom, stand-alone web-based system that we have developed to establish and implement secure methods for electronic OCT data submission from the CATT clinical study sites to the CATT OCT Reading Center, and to store and back-up submitted data. We will establish secure methods to transmit data from the OCT Reading Center to the Coordinating Center. The Reading Center will also implement materials and methods for grader, photographer, clinical coordinator and ophthalmologist certification and training, and support study goals as an image resource for recruitment, Study Group meetings, presentations and publications. ? ? ? ? ?
|Daniel, Ebenezer; Ying, Gui-Shuang; Kim, Benjamin J et al. (2018) Follow up at 5 Years of Non-Fibrotic Scars in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology :|
|Ying, Gui-Shuang; Maguire, Maureen G; Pan, Wei et al. (2018) Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials. Ophthalmol Retina 2:525-530|
|Rahimy, Ehsan; Ying, Gui-Shuang; Pan, Wei et al. (2018) EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. Retina :|
|Daniel, Ebenezer; Pan, Wei; Ying, Gui-Shuang et al. (2018) Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 125:1037-1046|
|Song, Delu; Ying, Gui-Shuang; Dunaief, Joshua L et al. (2018) ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. Retina :|
|Grunwald, Juan E; Pistilli, Maxwell; Daniel, Ebenezer et al. (2017) Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 124:97-104|
|Daniel, Ebenezer; Grunwald, Juan E; Kim, Benjamin J et al. (2017) Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmol Retina 1:25-33|
|Zhou, Qiang; Daniel, Ebenezer; Grunwald, Juan E et al. (2017) Association between pseudodrusen and delayed patchy choroidal filling in the comparison of age-related macular degeneration treatments trials. Acta Ophthalmol 95:e518-e520|
|Bevacizumab-Ranibizumab International Trials Group (2017) Serious Adverse Events with Bevacizumab or Ranibizumab for Age-related Macular Degeneration: Meta-analysis of Individual Patient Data. Ophthalmol Retina 1:375-381|
|Zhou, Qiang; Daniel, Ebenezer; Maguire, Maureen G et al. (2016) Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123:1530-40|
Showing the most recent 10 out of 35 publications